A5044092532- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Immune Cell Function and Interaction
- Wnt/β-catenin signaling in development and cancer
- vaccines and immunoinformatics approaches
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Hippo pathway signaling and YAP/TAZ
- Esophageal Cancer Research and Treatment
- CAR-T cell therapy research
- Fibroblast Growth Factor Research
- Multiple Myeloma Research and Treatments
Institute of Cancer Research
2019-2020
Institute of Cancer Research
2019
Abstract Aggressive behaviours of solid tumours are highly influenced by the tumour microenvironment. Multiple signalling pathways can affect normal function stromal fibroblasts in tumours, but how these events coordinated to generate tumour-promoting cancer-associated (CAFs) is not well understood. Here we show that expression Dickkopf-3 (DKK3) associated with aggressive breast, colorectal and ovarian cancers. We demonstrate DKK3 a HSF1 effector modulates pro-tumorigenic behaviour CAFs...
<h3>Background</h3> Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics investigate neoantigen presentation whether this augmented through interferon gamma (IFNγ) or MEK-inhibitor treatment. <h3>Methods</h3> Four microsatellite stable PDOs chemotherapy refractory one a treatment naïve CRC were expanded replicates with 100 million...
<h3>Background</h3> The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 cells, which triggers killing of lines expressing moderate to high levels CEA at the surface. Patient derived colorectal organoids (PDOs) may more accurately represent patient tumors than established potentially enables detailed insights into mechanisms resistance sensitivity. <h3>Methods</h3> We PDOs from multidrug-resistant metastatic CRCs. expression was...
Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The hypermutator-phenotype of dMMR tumours theoretically enables evolvability but evolution has not been investigated. Here we apply multi-region exome sequencing (MSeq) to four treatment-naive GOAs. This reveals extreme intratumour heterogeneity (ITH), exceeding ITH in other cancer types >20-fold, also long phylogenetic...
Abstract Background Gastric and gastro-esophageal junction cancers (GCs) frequently recur after resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic in other cancer types, not GC because of methodological limitations past studies. We aimed define validate the role major subtypes by objective computational quantification. Methods Surgically resected chemotherapy-naïve GCs were split into discovery (n = 327) validation 147)...
Abstract Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The hypermutator-phenotype of dMMR tumours theoretically enables evolvability but how these cancers evolve has not been investigated in detail. We applied multi-region exome sequencing (MSeq) to four treatment-naïve GOAs. This revealed extreme intratumour heterogeneity (ITH), exceeding ITH other cancer types...